Cookies on the
eqt
website
Our website uses cookies to improve your experience. By continuing to use this website, you are agreeing to our Cookie Policy.
Accept
EN
SV
中文
Toggle navigation
About EQT
Fast Facts
Values
About Value Creation
Portfolio Governance
Business Model
Future-proofing Companies
Long-term Perspective
Investment Characteristics
Organization
Investment Advisory Professionals
Fund Management
Client Relations and Capital Raising
Central Functions
EQT Network
Fund Investors
History
Funds
Active Funds
Realized Funds
Funds Structure
About the Industry
Business Segments
Private Capital
Private Equity
Mid Market Asia
Ventures
Public Value
Real Assets
Infrastructure
Real Estate
Credit
Credit
Investments
Current Portfolio
Divestments
Digital
Sustainability
Newsroom
Shareholders
About The EQT AB Group
Financial Reporting
Press Releases
IPO on Nasdaq Stockholm
Share Information
Share Capital Development
Shareholder Structure
Financial Targets and Dividend Policy
Corporate Governance
General Meetings
Nomination Committee
Board of Directors
Board Committees
Executive Committee
Remuneration
Incentive Programs
Auditors
Financial Calendar and Events
Glossary and Definitions
Shareholder Contacts
Subscribe
Careers
Working at EQT
Development
EQT Academy
Locations and Teams
Inclusion and Diversity
Join us
Recruitment Process
Join the EQT Talent Community
Offices
Contact
Search:
EN
SV
中文
Karo Intressenter AB owns approximately 66.5 per cent of the outstanding shares in Karo Pharma Aktiebolag after the expiry of the final acceptance period
14 February 2019
#Press Release
#EQT VIII
#Karo Pharma
14 February 2019
#Press Release
#EQT VIII
#Karo Pharma
For more information, click
here.